The SELECT trial studied the increase in risk for 35,533 men 50 years or older (African Americans) or 55 years or older (all others) with a prostate-specific antigen (PSA) ≤4.0 ng/mL and a digital rectal examination not suspicious for prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.